Also, the dual ALK/c-Met inhibitor crizotinib that is effective in treating EML4-ALK positive and c-Met amplificated NSCLC patients [624], induces apoptosis by a Bim-dependent mechanism [625]. Here, ALK is linked to non-small cell lung carcinoma.